1. Home
  2. YQ vs ATNM Comparison

YQ vs ATNM Comparison

Compare YQ & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

N/A

Current Price

$2.55

Market Cap

34.8M

Sector

Real Estate

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.07

Market Cap

31.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YQ
ATNM
Founded
2012
2000
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.8M
31.4M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
YQ
ATNM
Price
$2.55
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $4.50
AVG Volume (30 Days)
3.1K
★ 233.5K
Earning Date
12-08-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 14.17
EPS
N/A
★ 0.53
Revenue
N/A
★ $90,000.00
Revenue This Year
$274.52
$29,066.67
Revenue Next Year
$29.79
N/A
P/E Ratio
★ N/A
$2.06
Revenue Growth
N/A
★ 11.11
52 Week Low
$1.68
$0.74
52 Week High
$5.25
$1.72

Technical Indicators

Market Signals
Indicator
YQ
ATNM
Relative Strength Index (RSI) 37.29 35.95
Support Level $2.44 $0.91
Resistance Level $2.63 $1.21
Average True Range (ATR) 0.23 0.14
MACD -0.01 -0.06
Stochastic Oscillator 2.94 6.11

Price Performance

Historical Comparison
YQ
ATNM

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: